Novel approaches in primary cardiovascular disease prevention: the HOPE-3 trial rationale, design, and participants' baseline characteristics
Can J Cardiol
; 32(3): 311-318, 2016.
Artigo
em Inglês
| Sec. Est. Saúde SP, SESSP-IDPCPROD, Sec. Est. Saúde SP
| ID: biblio-1061782
Biblioteca responsável:
BR79.1
Localização: BR79.1
ABSTRACT
AbstractBACKGROUND:
Cholesterol and blood pressure (BP) can be effectively and safely lowered with statin drugs and BP-lowering drugs, reducing major cardiovascular (CV) events by 20%-30% within 5 years in high-risk individuals. However, there are limited data in lower-risk populations. The Heart Outcomes Prevention Evaluation-3 (HOPE-3) trial is evaluating whether cholesterol lowering with a statin drug, BP lowering with low doses of 2 antihypertensive agents, and their combination safely reduce major CV events in individuals at intermediate risk who have had no previous vascular events and have average cholesterol and BP levels.METHODS:
A total of 12,705 women 65 years or older and men 55 years or older with at least 1 CV risk factor, no known CV disease, and without any clear indication or contraindication to the study drugs were randomized to rosuvastatin 10 mg/d or placebo and to candesartan/hydrochlorothiazide 16/12.5 mg/d or placebo (2 × 2 factorial design) and will be followed for a mean of 5.8 years. The coprimary study outcomes are the composite of CV death, nonfatal myocardial infarction (MI), and nonfatal stroke and the composite of CV death, nonfatal MI, nonfatal stroke, resuscitated cardiac arrest, heart failure, and arterial revascularization.RESULTS:
Participants were recruited from 21 countries in North America, South America, Europe, Asia, and Australia. Mean age at randomization was 66 years and 46% were women.CONCLUSIONS:
The HOPE-3 trial will provide new information on cholesterol and BP lowering in intermediate-risk populations with average cholesterol and BP levels and is expected to inform approaches to primary prevention worldwide (HOPE-3 ClinicalTrials.govNCT00468923).
Buscar no Google
Coleções:
Bases de dados nacionais
/
Brasil
Contexto em Saúde:
Agenda de Saúde Sustentável para as Américas
/
ODS3 - Saúde e Bem-Estar
/
ODS3 - Meta 3.4 Reduzir as mortes prematuras devido doenças não transmissíveis
Problema de saúde:
Objetivo 9: Redução de doenças não transmissíveis
/
Meta 3.4: Reduzir as mortes prematuras devido doenças não transmissíveis
/
Doença Cardiovascular
Base de dados:
Sec. Est. Saúde SP
/
SESSP-IDPCPROD
Assunto principal:
Prevenção Primária
/
Doenças Cardiovasculares
/
Colesterol
/
Prevenção de Doenças
/
Pressão Arterial
Tipo de estudo:
Ensaio clínico controlado
/
Fatores de risco
Idioma:
Inglês
Revista:
Can J Cardiol
Ano de publicação:
2016
Tipo de documento:
Artigo
Instituição/País de afiliação:
College of Medicine of the University of the Philippines/PH
/
Dante Pazzanese Institute of Cardiology/BR
/
Department of Cardiology, Academic Medical Center/NL
/
Department of Epidemiology and Preventive Medicine, Monash University/AU
/
Department of Medical Sciences, Uppsala University/SE
/
Department of Medicine, McMaster University/CA
/
Diabetes Research Centre, University of Leicester/GB
/
Division of Clinical Research and Training, St. John's Research Institute/IN
/
Fu Wai Hospital, Chinese Academy of Medical Sciences/CN
/
Fundacion ECLA/AR